Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness

Abstract

Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.

Evolving Payer Coverage Policies on Genomic Sequencing Tests

“…A recent review found that only 6 cost-effectiveness analyses of next-generation sequencing testing in patients with cancer have been published, and 50% of these studies found that testing was not cost effective. 6 …”

DNA Encoded Glycan Libraries as a next-generation tool for the study of glycan-protein interactions

“…In this study, we processed 72 samples in a single assay using 36 DNA barcodes, and each barcode received ~80,000 reads (ion 520 chip, 3-6 million reads). When bigger chips are used to their full capacity, 5 million reads of NGS can be currently obtained for $200 [56], driving down costs.…”

P5 eHealth: An Agenda for the Health Technologies of the Future

“…Costs of targeted gene panels vary widely, mainly depending on the numbers of genes sequenced. For example, a recently published nationwide French study reported a cost ranging between €376 and €968 (Marino et al 2018), whereas the cost-effective analysis conducted on 10 studies by Tan et al calculated an average cost of $1609 USD per sample (range: $488-$3443 USD) (Tan et al 2018). The authors observed that cost of sequencing is generally lower if performed in-house compared to outsourcing to a service provider.…”